Evorin pharma

Directions Website

Evorin pharma http://evorin.com/ Professional treatment with the most scientifically advanced solutions

Evorin pharma is a leading health services and innovation company on a mission to continuously generate groundbreaking ideas in the name of Health and beauty. We have years of experience in developing innovative products and unique treatment methods and we promise to continue this tradition of excellence. Building a unique portfolio of Health and beauty and related brands, striving to surpass competitors in quality, innovation, and value, and elevating Evorin's image to become the world's most trusted Pharmaceutical and Cosme-ceutical company.

Medical Technologies and Innovation InternThis internship is part of an academic training program, a professional traini...
15/10/2026

Medical Technologies and Innovation Intern

This internship is part of an academic training
program, a professional training program, or a
socio-professional integration program, and must
comply with the conditions set by the Employment
Market Supervisory Council (CSME). The duration
of the internship, as defined by the tripartite
agreement, is 6 to 12 months at 100%

Inclusivity and Diversity at MSF

Do your qualifications and experience not exactly
match all requirements of the job?

At MSF OCG, we are committed to an inclusive
culture that supports and amplifies the diverse
voices of our staff members. We strive to create
workplaces where teams of people with diverse
backgrounds, characteristics, perspectives, ideas
and experiences work together to advance MSF's
social mission and create better outcomes for our
patients and the communities we work with.

We understand that some people may hesitate to
apply for employment if they don't meet all
listed job requirements. Research shows that this
is especially true for women. If you believe your
profile is a good match for this position, we
invite you to apply even if you don’t fulfil
every listed qualification.

We encourage applications from individuals of all
genders, ages, sexual orientations, ethnicities,
background, religions, beliefs, ability status,
and all other diversity characteristics.

MSF does not tolerate sexual exploitation and
abuse, any kind of discrimination or harassment,
including sexual harassment. All selected
candidates will undergo reference checks.

Context & mission

Médecins Sans Frontières is an independent,
international medical and humanitarian
organization that provides care to people in
need, people affected by natural or man-made
disasters, and victims of armed conflict, without
discrimination and without regard to race,
religion, creed or political affiliation (MSF
Charter).

The MSF movement is built around 5 operational
centers supported by 24 sections and offices
worldwide. MSF Operational Center Geneva (MSF
OCG) is one of these centers.

OCG has a long history of supporting Medical
Technologies and Innovation, as an early adopter
of innovation in humanitarian organizations in
the early 2000s. It continues to work to leverage
medical technology and innovation advances in
line with the strategic objectives through a mix
of key transformational initiatives, and quick
wins that utilize existing tools through
acceptable adaptation process. Emphasis and focus
are placed on field driven initiatives and
scalable tools that mirror current OCG ambitions,
achieving transparency, proactive communication
and prioritization through a platform-based
repository for innovations. The current Medical
Technologies unit consists of the Medical
Technologies and Innovation Coordinator, and the
Digital Health Advisor, who focuses on projects
and challenges in the digital health space.

Advances in New Functional Biomaterials for Medical Applications, Second EditionRapid advances in the field of functiona...
01/10/2026

Advances in New Functional Biomaterials for
Medical Applications, Second Edition

Rapid advances in the field of functional
biomaterials are opening up new perspectives for
the development of innovative medical solutions
capable of meeting the current demands of
regenerative medicine, diagnostics, and
personalized therapy with increasing efficiency.
This Special Issue, titled “Advances in New
Functional Biomaterials for Medical Applications,
Second Edition,” presents new interdisciplinary
research with innovative potential for the
development of modern medicine.
The history of biomaterials is closely linked to
the evolution of medicine and the ongoing need to
replace, repair, or support the functions of
damaged tissues and organs. From the early use of
natural materials and metals in sutures,
prostheses, or implants, the field has evolved
toward materials specifically designed to
interact with biological systems in a controlled
manner [1,2]. In recent decades, the focus has
shifted from simple biocompatibility to
functional, bioactive, and smart biomaterials
capable of stimulating tissue regeneration,
delivering therapeutic agents in a controlled
way, or responding to specific stimuli within the
biological environment.
In recent decades, this evolution has accelerated
significantly. Contemporary biomaterials are no
longer simple structural substitutes; instead,
they can perform well-defined biological,
mechanical, antimicrobial, diagnostic, or
therapeutic functions. Nanotechnology, surface
functionalization, the development of hybrid
materials, additive manufacturing methods, and
the integration of biomaterials with modern
imaging techniques have significantly expanded
the possibilities for designing materials for
medical applications. In this context, the
concept of the “functional biomaterial” is taking
on an increasingly broad meaning, encompassing
materials capable of responding to the biological
environment, combating microorganisms,
facilitating tissue regeneration, improving
diagnostics, or providing mechanical and
aesthetic performance tailored to specific
clinical applications.
Sustainability and the development of
environmentally friendly synthesis methods also
represent an important direction in current
research. The use of plant-derived compounds to
produce nanomaterials, reduce chemical
consumption, and utilize natural resources aligns
with the broader concept of “green”
nanotechnology. Concurrently, medicine and
dentistry are benefiting from increasingly high-
performance materials; their application requires
not only suitable intrinsic properties but also a
deep understanding of surface behavior, adhesion
processes, aging, and long-term interactions with
the biological environment.

An Overview of Thematic Contributions
The papers collected in the second edition of the
topic “Advances in New Functional Biomaterials
for Medical Applications” illustrate this
diversity in contemporary research and highlight
the field’s deeply interdisciplinary nature.
Ranging from nanomaterials with antimicrobial
properties and systems with diagnostic potential
to advanced dental materials and novel
manufacturing technologies, the studies presented
demonstrate how controlling composition,
structure, and surface characteristics can
determine a biomaterial’s functionality.
The first contribution explores a major avenue of
current research: the development of
antimicrobial nanomaterials using sustainable
synthesis methods. Utilizing mucilage from
*Prosopis laevigata* for the eco-friendly
synthesis of silver nanoparticles combines the
advantages of nanotechnology with the utilization
of plant resources. The antimicrobial and anti-
biofilm activity demonstrated against Gram-
positive and Gram-negative pathogens, alongside
findings regarding biocompatibility, highlights
the potential of these nanoparticles for
developing antimicrobial coatings, topical
treatments, and strategies to control microbial
contamination. The study is also relevant in the
context of growing concerns regarding
antimicrobial resistance, highlighting the need
to identify strategies complementary to
conventional antibiotics.
Another significant group of contributions
focuses on dental biomaterials, a field where
mechanical, biological, and aesthetic
requirements must be met simultaneously. The
study on resin-matrix ceramics underscores the
importance of surface treatment for maintaining
the color stability of restorations. The results
demonstrate that the nature of the material, the
finishing procedure, and exposure to various
beverages can all influence color changes. The
observation that mechanical polishing may be a
favorable option for CAD/CAM restorations
highlights the role of clinical processing steps
in preserving the biomaterial’s aesthetic
properties over the long term.
The issues surrounding the interface between the
material and the adhesive system are examined in
depth in the study on lithium silicate-based
glass–ceramics. In restorative practice, a
material’s performance is determined not only by
its structural characteristics but also by the
ability to achieve and maintain predictable
adhesion. An evaluation of various re-cementation
strategies highlights the importance of
optimizing surface treatment and suggests that
controlled hydrofluoric acid etching can be an
efficient and reproducible approach. At the same
time, results regarding air-particle abrasion
show that an apparently favorable increase in
contact surface area does not automatically
translate into superior adhesion, underscoring
the complex relationship between surface
topography and the mechanical behavior of the
adhesive interface.
A different perspective on functional
biomaterials is offered by the study on magnetite
nanoparticles functionalized with carboxymethyl
cellulose. In this instance, the material’s
functionality extends beyond structural or
therapeutic roles into the realm of diagnostics.
The biocompatibility of the resulting assemblies
and their dielectric properties suggest they
could serve as contrast agents for terahertz
spectroscopy. Identifying a spectral range where
the differentiation between normal and tumor
cells becomes significant highlights the
potential for integrating nanomaterials with
emerging imaging technologies and opens up
exciting prospects for developing complementary
diagnostic methods in oncology.
Finally, the evolution of biomaterials is closely
linked to the revolution in manufacturing
technologies. The study focusing on zirconia
produced via lithography-based ceramic
manufacturing (LCM) analyzes the feasibility of
using additive manufacturing to create dental
restorations subject to mechanical stress.
Flexural strength comparable to that of
conventionally manufactured zirconia demonstrates
the potential of these technologies, while
observed differences in hardness and surface
roughness highlight the need for further
optimization of manufacturing and post-processing
procedures. Thus, additive manufacturing
represents not merely a technological alternative
to subtractive methods, but also a tool for the
future design of customized biomaterials and
structures.

Conclusions and Future Directions
Taken together, these contributions underscore
the ongoing transformation of the biomaterial
concept. Functionality is no longer defined by a
single property, but rather by the material’s
ability to simultaneously meet biological,
mechanical, chemical, antimicrobial, aesthetic,
or diagnostic requirements. Surface and interface
control, nanostructuring, chemical
functionalization, sustainable synthesis, and
digital manufacturing now constitute
complementary elements of the same development
trajectory.
This second edition therefore highlights the
transition from conventional biomaterials to
multifunctional systems designed for increasingly
specific medical applications. The collected
studies demonstrate that progress in this field
stems from the convergence of materials science,
chemistry, nanotechnology, engineering, biology,
and medical practice. It is precisely this
interdisciplinarity that lays the groundwork for
the development of the next generation of
biomaterials, in which material performance will
be increasingly linked to adaptability,
functionality, and the ability to address precise
clinical needs.

Advanced Therapies: Invention or Innovation?Scientific breakthroughs are only true innovations if healthcare systems can...
24/09/2026

Advanced Therapies: Invention or Innovation?
Scientific breakthroughs are only true

innovations if healthcare systems can deliver
them safely, manage their toxicities, and make
them accessible at scale

Imagine working in a hospital that cannot access
or safely deliver the medications needed to treat
your patients? For anybody working in
healthcare, this doesn’t take imagination. It is
an experience frequently encountered and for a
myriad of different reasons from economic to
resourcing to infrastructural limitations. But
imagine intentionally spending years and hundreds
of millions on developing new medicines that
either can’t be delivered or don’t have an
addressable population? It may sound bizarre but
less so to those working within pharmaceuticals.
Healthcare systems adapt, that is their role,
they adapt so that they can effectively treat
patients. It aims for structure within a fluidly
evolving treatment landscape, but there are
trade-offs and there are practical limitations.
Evolving takes time.

Cell therapies have emerged as the pre-eminent
achievement of synthetic biology in the 21st
century, with potentially curative outcomes in
late-stage treatment refractory cancers, and
promise in genetic, rare and autoimmune diseases.
In vivo CAR gene therapies offer an off-the-shelf
alternative that can bypass complex manufacturing
and logistics, potentially expanding access to
many more patients but scalability is still a
major question. Could these move into front-line
settings? Could they virtually eliminate late-
stage diseases and mortality? But are these
therapies sufficiently scalable to reach all
patients?

We have been here before. The first cytotoxic
chemotherapies emerged in the 1940s from an
unlikely source – chemical warfare research,
after mustard gas exposure was observed to
suppress the bone marrow. When nitrogen mustard
was first turned against lymphoma, the drug
worked, but severe myelosuppression, intractable
nausea and life-threatening infection meant that,
for years, the treatment could be nearly as
perilous as the disease. It was only decades
later, with the arrival of effective antiemetics,
granulocyte colony-stimulating factors and
antibiotic prophylaxis, that chemotherapy could
be given at the doses and scale its promise
demanded. There are lessons here that we should
apply again today.

Patient need

Healthcare infrastructure throughout the world
varies significantly between and within
countries. There is no one model, and effective
solutions need to be flexible to work within
diverse healthcare settings. In the USA, by some
estimates, less than 20 percent of cancer
patients are treated in large hospitals. By
contrast, in the hub and spoke system across much
of Europe, virtually all cancer patients are
treated under the auspices of large hospitals.
Although large US centers often appear to have
the resources to lead innovation and adapt to
challenges, arguably, Europe may be better placed
when it comes to broadly embedding new
technologies.

There is a strong global movement at present to
broaden access to cell therapies and other
advanced therapies like bispecific antibodies,
particularly in the US where some estimates
suggest up to 80 percent of cancer care occurs in
the community setting. Multiple efforts are
ongoing to democratize access by broadening the
availability of emerging therapeutics into the
community, but challenges persist. Recently,
pharmaceutical companies have been making efforts
to launch drugs into large treatment centers
along with smaller centers and community
treatment centers by including these sites within
their clinical trials.

There are significant challenges ahead to
universally broaden access. Educational programs
are well placed to reach all sites, providing the
training tools and the resourcing blueprints
needed. Recently, key opinion leaders across a
range of malignancies have been urging community
doctors and patients themselves to demand access
to these emerging therapies and to act as the
catalyst needed for change.

Broadening access to emerging therapies

Similarly to the first chemotherapies, emerging
medicines come with bespoke challenges. Cell
therapies and bispecific antibodies are
associated with severe and prolonged
hematological toxicities. Certain patients
receiving bispecific antibodies can spend over
100 days in hospital during their first year of
treatment and so even where access is universal,
practical concerns, such as caregiving at home
can affect patient choice, but providing patient
access is the first hurdle.

There are also existential challenges. The
skillsets required to manage patients on these
therapies are typically held by hematologists,
but with application extending into solid
cancers, autoimmune diseases and beyond, who is
going to manage these patients? Other than having
many more hematologists, the successful delivery
of these therapies will require whole new medical
disciplines to be upskilled.

Scalability requires methods to reduce non-
relapse-related morbidity, and to find ways to
put the brakes on treatment-related toxicities.
Either we replace the existing therapies with
more tolerable versions, or we expand the toolkit
to better manage the toxicities. Drug development
is inherently expensive, lengthy, and risky,
therefore simply waiting for more tolerable
therapies is not realistic.

Addressing systemic barriers

Today the supportive care toolkit (the medicines
used to manage toxicities) is largely unchanged
from a few decades ago. The regulatory pathways
for supportive care drug development are poorly
suited, and inward investment in this area has
been chronically weak. Indications can be
difficult to define; therapeutic benefits can be
difficult to measure; and intra-trial subjects
can have diverse underlying diseases making drug
development in these areas challenging.
Curiously, in Europe, the EMA does not typically
consider iatrogenic conditions – that is,
conditions caused by medical interventions – as
eligible for orphan protection, further limiting
incentives to address these important unmet
medical needs.

Lack of innovation has meant that clinicians
largely rely on repurposed options. But
reimbursement for repurposed medications can be
notoriously difficult. In the UK, the NICE single
technology appraisal system has only overseen a
handful of non-pharmaceutical sponsored
submissions. And further challenging their use,
drugs that are not available in the supply chain
and are used off-label often need to be requested
from the manufacturer on a named patient basis.

Take Cytokine Release Syndrome (CRS) as an
example. Up until the first CAR T-cell approval
in 2017, CRS was largely unknown. It was seen
sporadically in the literature but became
ubiquitous as CAR T-cell and T-cell engaging
therapies progressed into clinical trials.
Immunotherapy-induced CRS is a distinct
condition. In many ways, it is an ideal condition
for drug development. Tocilizumab, an IL-6
monoclonal antibody, and steroids have become the
mainstay of treatment. There is strong supporting
evidence for this treatment option, but this
comes from many sources and without properly
powered studies there isn’t a firm understanding
of their long-term effects on related conditions,
with some suggesting that they could be
counterproductive by increasing neurological
toxicities. Whatever the case, there is a strong
demand from the healthcare system for an
effective preventative CRS treatment. Beyond its
direct effects on reducing the intensive
monitoring requirements, and in some cases
hospitalization periods, there is a larger
picture that effective supportive care therapies
may play a pivotal role in equitable access to
medicine for all. A risk of hospitalization may
appear low, but to a late-stage cancer patient,
or a patient with family circumstances requiring
their presence at home; these are major factors.

Health economists sometimes ask, provocatively,
whether medicine is an invention or an
innovation. There is no doubt that we are living
through a boom in medical invention, but
scientific breakthroughs alone will not ensure
that advanced therapies reach the patients who
need them. There is a perception that we will
solve these problems by developing iteratively
safer and more effective drugs but this is a
linear, cumbersome and wasteful solution to an
intractable challenge. To turn invention into
innovation, we must with vigor and enthusiasm
proactively develop the supportive care
medicines, the clinical expertise, and
infrastructural healthcare models required to
manage these treatments safely and at scale. Only
then can the promise of these breakthrough
therapies be fully realized.

Medicines do no good if people don’t take themHealth psychologist Rob Horne explains why medication non-adherence is suc...
10/09/2026

Medicines do no good if people don’t take them
Health psychologist Rob Horne explains why medication non-adherence is such a problem, and how behavioural science can help to address it.

A treatment can be effective only if a person takes it as prescribed — but many people choose not to do so. Rob Horne, a health psychologist at University College London, spoke to Nature about how the psychology of non-adherence can help people get the most from their treatments.

What is medication non-adherence?
Non-adherence covers three distinct behaviours: whether a person starts taking medication (initiation); whether they take it correctly (ex*****on); and whether they stay the course for as long as prescribed (persistence). The World Health Organization estimates that around half of people prescribed drugs for long-term conditions are non-adherent in one way or another. The problem cuts across every disease, health-care system and country: even orally administered cancer medicines commonly have non-adherence rates above 20%.

Why does non-adherence matter?
What makes a pharmaceutical effective is two things: what’s in the drug, and what else you put in the box with it to ensure that people take it correctly. The industry is very good at the first and not so good at the second. Non-adherence costs the United States around US$530 billion a year, and is linked to roughly 125,000 deaths there. In my view, this is one of the biggest problems in medicine.

Why do people choose not to take the medicines that are available to them?
There are two key beliefs that drive people to make that decision. The first is that they don’t believe the medication is necessary. That’s not simply whether they think it works, but also whether they think its effects are valuable to them. Someone who has been prescribed a drug for high blood pressure might feel absolutely fine and therefore not see the need to control it.

The second crucial element is people’s concerns about taking the medication: what downsides do they believe there to be? Side effects are part of this, but people worry about much more than that.

A man in his forties who has never taken regular medication might resist taking a statin, not because he doubts that it works, nor because he fears side effects, but because it conflicts with his sense of who he is. He doesn’t see himself as someone who has to take medicines every day for life.

How can those beliefs be changed?
We first have to understand that most of these beliefs are not irrational: they are logical, given how people experience illness. Until someone is diagnosed with a long-term condition, most of their lived experience of being ill is symptomatic and episodic — they feel unwell, they get treatment, they feel better, they stop treatment. But conditions such as asthma, inflammatory bowel disease and arthritis don’t work like that — there is often no clear relationship between what a person feels during flare-ups and remissions, and what is actually happening in their body. When someone stops feeling symptoms, they might conclude they will no longer benefit from the medicine, and focus instead on its downsides.

To improve adherence, health-care professionals must understand an individual’s beliefs. A man who doesn’t want to be a person who takes statins every day will not be swayed by more facts about cardiovascular risk. What he needs is an open conversation that starts from the assumption that hesitation is common and reasonable, and finds out what lies behind it for him. Then we can tailor the conversation to that specific belief.

Can a reminder app on a phone help?
Reminder systems that alert someone that it’s time to take their medicine are not enough. That’s not addressing non-adherence, that’s an alarm clock. Reminders improve a person’s ability to adhere when they already want to, but to really shift the dial we need to address both the perceptual and the practical barriers to adherence.

Our research shows that personalized support, delivered by health-care professionals and digital systems, can do that effectively.

What changes would you like to see in how drugs are developed and prescribed?
I would mandate the inclusion of regulator-approved, science-based adherence support as part of the cost of developing and prescribing a medicine. When a health system pays for a medicine, that outlay should cover adherence support, and that support should have to meet the same quality standard as the drug itself. When a drug loses its patent protection, makers of generics should be required to provide equivalent adherence support.

That’s the ideal. Because if adherence support is part of what you pay for when you buy a medicine, then patients and their families, the health systems that pay for drugs, and the pharmaceutical industry selling them, would finally have a shared incentive to fix the problem together.

How important is it that medication adherence be improved?
There are effective drugs for hypertension, type 2 diabetes, and mild-to-moderate asthma already — the challenge is getting people to take them. Even a single-percentage-point improvement in adherence to essential medicines would make a significant difference in reducing the cascade of effects that stem from under-treatment. Developing new drugs is important, but it should be much less costly and quicker to maximize the benefit of the medicines that we’ve already got.

3 Health Innovations That Would Not Exist Without AIArtificial intelligence (AI) is making headlines practically every d...
03/09/2026

3 Health Innovations That Would Not Exist Without
AI

Artificial intelligence (AI) is making headlines
practically every day. Some praise its ability to
provide new medical insights, while others point
to concerning privacy risks with the technology
in healthcare. The headlines are polarising, to
say the least.

While some of AI’s potential has been overhyped
for marketing purposes, its importance in
healthcare remains undeniable. As such, to put
the benefits of AI in healthcare in context, we
share three developments that would not be
possible without the technology.

1. Drug discovery: solving biological puzzles
Let’s start with a strong example: some life-
saving drugs wouldn’t exist without the help of
AI. In particular, the technology has made leaps
in the drug discovery process, or the first stage
of drug development. This involves identifying a
target protein that is associated with a disease,
and selecting molecules, which become initial
drug candidates, that can bind to and influence
the target.

This puzzle-like process is an intensive and
time-consuming one that can benefit from the help
of AI. Algorithms can be used to predict
characteristics of a candidate and whether it
will be effective and safe.

This is what drug discovery software developer
Schrödinger does. It employs AI models to predict
how molecules will behave and the possible
outcomes, based on their respective parameters.
The company’s tools have been adopted by pharma
companies such as Pfizer and AstraZeneca.

Another notable example comes from Google
DeepMind’s AlphaFold. This AI model can
accurately predict how potential candidates bind
to proteins and influence human disease. The
achievement was so transformative that its
developers were awarded the 2024 Nobel Prize in
Chemistry.

Isomorphic Labs, a spinoff of DeepMind, utilises
AlphaFold and its own AI models to improve drug
design for projects with its pharmaceutical
partners. The company plans to start human trials
of drugs designed by its AI technology.

2. Medical imaging: a second pair of eyes
Medical imaging represents another area where AI
has enabled capabilities that previously did not
exist. Clinicians interpret thousands of images
every week, often under considerable time
constraints. AI systems can assist in the task of
identifying subtle abnormalities and flagging
suspicious lesions. In fact, radiology is the
medical field with the highest number of AI
initiatives.

An example of such systems is the FDA-approved
IDx-DR. It allows patients to be screened
directly within primary care settings,
potentially identifying vision-threatening
disease much earlier.

The FDA-cleared AI-powered platforms from Viz
also provide medical imaging support. They can
detect suspected vessel occlusions and risk of
stroke in CT scans, thereby alerting specialists
to take preventative measures.

Such AI assistance in medical imaging can
directly impact patient outcomes. Importantly,
these systems do not replace radiologists. They
function as intelligent assistants that monitor
scans, helping clinicians focus their expertise
where it is needed most.

3. Personalised care: a unique healthcare
experience
An enduring aspiration for the healthcare field
has been personalised care, that is, delivering
treatment that is tailored to an individual’s
personal needs. However, the sheer complexity of
individual biologies has made this prospect
unattainable for as long as medical practice has
existed. AI has brought this ideal healthcare
experience closer to reality.

With their ability to crunch vast amounts of data
and mine insights, AI systems can integrate
medical data from a range of sources, from
genomic analyses to wearable data, to offer
tailored insights.

Dutch researchers developed an AI system that
provides optimised plans for the radiation of
prostate cancer in record time. The AI created
better plans and more insight than the doctors
thought possible.

In the U.K., Addenbrooke’s Hospital in Cambridge
uses Project InnerEye, an AI tool supporting the
treatment of cancer patients. The AI analyses
hospital data to identify tumours on patient
scans and ensures that their treatment plans are
tailored to them individually.

While true personalised medicine remains a work
in progress, AI has become one of the essential
technologies making it feasible.

The real potential of AI in healthcare
While it can be tempting to view every healthcare
AI announcement as another revolution, the
reality is more nuanced. A lot of these
announcements are based on AI systems tested in
controlled and limited research settings.
Evidence is crucial in implementing such systems,
hence the importance of oversight from regulatory
bodies such as the FDA.

Despite some concerns over AI taking over the
jobs of clinicians and scientists, the real
potential of the technology does not lie in
replacing them. Instead, it’s in supporting them
to explore avenues that would have been
practically impossible using conventional methods
alone. From designing new drugs to making
personalised medicine a reality, AI is beginning
to create medical possibilities rather than
merely automate existing work.

Address

UK Address: PLUM TREE HOUSE/OLD VICARAGE Lane SWINDON/UNITED KINGDOM/SN3 4SH : Dubai Address:Office No. 2108, Jumeirah Bay Tower/Dubai/
Dubai

Opening Hours

Monday 08:00 - 18:00
Tuesday 08:00 - 18:00
Wednesday 08:00 - 18:00
Thursday 08:00 - 18:00
Sunday 08:00 - 18:00

Website

Alerts

Be the first to know and let us send you an email when Evorin pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Category